Delivery Order SPE2DB20D9214-SPE2DB25FD4WV
- Not listed
- The Defense Logistics Agency awarded a $16,249.95 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Stelara 90 mg/ml syringes on July 22, 2025, with an ultimate completion date of August 12, 2025. This delivery order was issued without a set-aside designation and will be performed in Park Ridge, Illinois, where the vendor is headquartered. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is the prime contractor on this award. This delivery...
- On August 18, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $32,499.90 to DMS Pharmaceutical Group Inc. for the supply of Stelara 90 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its facility in Park Ridge, IL. This award represents a firm fixed-price delivery order under the company's larger Indefinite Delivery Contract with the DLA, valued...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc. for the supply of Stelara 90 mg/ml syringes, with an ultimate completion date of September 3, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order will be fulfilled at the contractor's facility in Park Ridge, IL. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on July 29, 2025, for the supply of Stelara 90 mg/mL syringes with a ceiling value of $16,249.95. This firm fixed-price delivery order is expected to reach ultimate completion by August 19, 2025, with performance taking place at the contractor's facility in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an open basis despite its status as a...
- On August 1, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc. for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, which is scheduled for completion by August 22, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves as the prime contractor on this award. The delivery order is...
- The Defense Logistics Agency awarded a $16,249.95 delivery order to DMS Pharmaceutical Group Inc. on August 20, 2025, for the supply of Stelara 90 mg/ml syringes. This contract award was issued without a set-aside designation, leveraging open competition. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its Park Ridge location with an ultimate completion date of September 11, 2025. The contract...
- The Defense Logistics Agency awarded a delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. This firm fixed-price delivery order, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, carries no set-aside designation. The award represents a single transaction under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc. on August 19, 2025, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order is set to be completed by September 10, 2025, with performance taking place at the vendor's facility in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an open basis despite its status as a woman-owned small business. This...
- This delivery order, issued on August 8, 2025, by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, covers the supply of Stelara 90 mg/ml syringes with a ceiling value of $16,249.95. The contract is a firm fixed-price delivery order with an ultimate completion date of August 29, 2025, and represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $16,249.95 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 22, 2025, for the supply of Stelara 90 mg/ml syringes. The award carries an ultimate completion date of August 12, 2025, and involves no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its facility in Park Ridge. This delivery order falls under the...
- SPE2DB20D9214Indefinite Delivery Contract
- SPE2DB20D9214-SPE2DB25FD4WVDelivery Order
The Defense Logistics Agency awarded a $32,499.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on August 7, 2025, for the supply of Stelara 90 mg/mL syringes. The contract, which carries no set-aside designation, is scheduled for completion by August 28, 2025, with performance conducted at the vendor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler that has been registered in the System for Award Management since 2001 and specializes in providing comprehensive pharmaceutical products and medical supplies to federal agencies, particularly the Department of Defense. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The IDC enables the issuance of firm fixed-price delivery orders for an extensive portfolio of pharmaceutical items supporting medical supply needs across military health facilities worldwide. Stelara, an immunosuppressive biologic medication, represents one of the specialized pharmaceutical products within the company's federal contract portfolio, which also includes prescription medications, biologics, and medical consumables serving Department of Defense healthcare sites.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.5k | 8/7/25 |